A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults
Open Access
- 16 December 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 17 (3) , 551-560
Abstract
Objective. This randomized, double-blind, placebo-controlled, crossover trial evaluated the pharmacodynamic effects of a single 100-mg dose of ABT-639, a peripherally active, selective T-type Cav3.2 channel blocker, with the intradermal capsaicin pain model using pregabalin 300 mg as a positive control. Subjects. Healthy adult males (aged 21 to 55 years) were randomly assigned to receive single oral doses of ABT-639, pregabalin, and placebo. Methods. Serial measurements for area (cm2) of hyperalgesia, allodynia, and flare response were performed over a 20-minute period after each capsaicin injection at 1 and 4 hours post-dose. Capsaicin injections were administered in different arms as determined by random assignment. Serial measurements for spontaneous pain and elicited pain were performed over a 60-minute period at 1 and 4 hours post-dose using a 100-mm visual analog scale. Standard safety evaluations were performed. Results. Nineteen participants were randomized and included in the analysis. No significant differences were observed between ABT-639 and placebo in spontaneous pain, elicited pain, and areas of allodynia, hyperalgesia, and flare after intradermal capsaicin injection at 1 and 4 hours post-dose. In contrast, pregabalin demonstrated significant reductions in spontaneous pain at 1 and 4 hours post-dose, and elicited pain and areas of allodynia and hyperalgesia at 4 hours post-dose compared with placebo. ABT-639 demonstrated acceptable safety and tolerability; somnolence and euphoric mood were the most commonly reported adverse events. Conclusions. These data indicate that a single 100-mg dose of ABT-639 had no effect on experimental pain induced by intradermal capsaicin injection.Keywords
This publication has 30 references indexed in Scilit:
- Involvement of the endogenous hydrogen sulfide/Cav3.2 T‐type Ca2+ channel pathway in cystitis‐related bladder pain in miceBritish Journal of Pharmacology, 2012
- Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic DrugsPharmacological Reviews, 2012
- TTA-P2 Is a Potent and Selective Blocker of T-Type Calcium Channels in Rat Sensory Neurons and a Novel Antinociceptive AgentMolecular Pharmacology, 2011
- T‐type voltage‐gated calcium channels as targets for the development of novel pain therapiesBritish Journal of Pharmacology, 2011
- Clinical Pharmacokinetics of Pregabalin in Healthy VolunteersThe Journal of Clinical Pharmacology, 2010
- Upregulation of Cav3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic painPain, 2010
- In vivo silencing of the CaV3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathyPain, 2009
- Effect of Morphine and Pregabalin Compared With Diphenhydramine Hydrochloride and Placebo on Hyperalgesia and Allodynia Induced by Intradermal Capsaicin in Healthy Male SubjectsThe Journal of Pain, 2008
- Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy VolunteersAnesthesiology, 2007
- The Effect of Chronic Oral Desipramine on Capsaicin-Induced Allodynia and Hyperalgesia: A Double-Blinded, Placebo-Controlled, Crossover StudyAnesthesia & Analgesia, 2002